Pfizer(FRA) PFE

Pfizer Inc. operates as a global biopharmaceutical enterprise, dedicated to the discovery, development, production, marketing, and distribution of a wide array of medicinal and vaccine products across the globe. Established in 1849, Pfizer maintains its corporate headquarters in New York City and has a diverse portfolio addressing numerous therapeutic areas.

Products and Services

• Medicinal products for cardiovascular, metabolic, and women's health
• Vaccines for diseases including COVID-19 and pneumococcal disease
• Contract manufacturing services for various pharmaceutical needs

Growth Outlook

• Recent quarterly revenue of €15.03 billion shows strong market demand
• Continued investment in R&D with €2.81 billion allocated last quarter
• Strategic collaborations with industry leaders enhance growth potential

Financial Highlights

• Trailing twelve months (TTM) revenue of €59.73 billion reflects solid performance
• Net income margin of 6.81% indicates profitability despite recent challenges
• Dividend yield of 6.08% offers attractive returns for investors

Pfizer Inc. has established itself as a leader in the biopharmaceutical industry, with a robust portfolio that includes both innovative therapies and essential vaccines. The company's commitment to research and development is evident in its significant investment, which positions it well for future growth. Recent financial performance highlights a strong revenue base and profitability, despite facing challenges in the market. The attractive dividend yield further enhances its appeal to potential investors. With strategic partnerships and a focus on expanding its product offerings, Pfizer is poised for continued success in the evolving healthcare landscape.